# Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
Canonical URL: https://biopharmsignal.com/news/SEER/seer-board-of-directors-unanimously-rejects-further-revised-unsolicited-proposal-from-radoff-jec-group
Ticker: SEER
Company: Seer, Inc
Source: Seer, Inc
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.seer.bio
## Summary

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited

## Article Body
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited
## Recent Company News
- 2026-07-06 11:00 EST — [Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential](https://biopharmsignal.com/news/SEER/seer-files-investor-presentation-highlighting-strong-momentum-commercial-opportu-e67fff29) — Source: Seer, Inc
- 2026-07-02 21:00 EST — [Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.](https://biopharmsignal.com/news/SEER/seer-announces-receipt-of-unsolicited-acquisition-proposal-from-omid-farokhzad-m-c91bb35c) — Source: Seer, Inc
- 2026-07-01 11:00 EST — [Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics](https://biopharmsignal.com/news/SEER/seer-prevails-in-european-patent-opposition-as-u-s-itc-opens-investigation-into--47d79284) — Source: Seer, Inc
- 2026-06-25 13:46 EST — [Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening](https://biopharmsignal.com/news/SEER/seer-and-korea-university-present-preliminary-data-at-asms-2026-demonstrating-potential-of-ai-driven-plasma-proteomics-for-multi-cancer-screening) — Source: Seer, Inc
- 2026-06-25 13:46 EST — [Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign](https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-highlighting-the-company-s-significant-scientific-progress-and-addressing-radoff-and-torok-s-short-sighted-campaign) — Source: Seer, Inc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)